An ultrasensitive method for the measurement of haloperidol and reduced haloperidol in plasma by high-performance liquid chromatography with coulometric detection.
A new analytical method has been developed for the simultaneous quantitation of haloperidol and reduced haloperidol in plasma. The method is based on high performance liquid chromatography (HPLC) with coulometric detection. The extraction and sample clean up procedures are simple and rapid to execute, yet yield chromatograms virtually free of interference from endogenous plasma constituents, such that the extraordinary sensitivity of the coulometric detector can be exploited fully. The detection limits for haloperidol and reduced haloperidol are 20 pg/ml plasma, and the limits of quantitation are 50 pg/ml for both drug and metabolite. Standard curves were linear down to 50 pg/ml with coefficients of variation of less than 7.0% at the limits of quantitation. The method was applied to the study of the plasma levels of haloperidol and reduced haloperidol in two healthy subjects. It was possible to monitor the plasma levels of haloperidol for at least 96 h (4 days) after the administration of a 5-mg oral dose of haloperidol. It was also possible to monitor reduced haloperidol levels over 96 h in one subject, although the metabolite was not detectable in the plasma of the other at any stage.
Midha
K K
KK
College of Pharmacy, University of Saskatchewan, Saskatoon, Canada.
Cooper
J K
JK
Hawes
E M
EM
Hubbard
J W
JW
Korchinski
E D
ED
McKay
G
G
D002851:Chromatography, High Pressure Liquid; D004563:Electrochemistry; D006207:Half-Life; D006220:Haloperidol / Q000097:blood*; D006801:Humans; D008297:Male; D011786:Quality Control
D006220:Haloperidol